Comparison of Adverse-Event Profiles of Intravenous Low-Molecular-Weight Iron Dextran and Iron Sucrose in Peritoneal Dialysis Patients

REFERENCES

• Locatelli F, Del Vecchio L, Pozzoni P. Treating anemia at different stages of renal disease. J Nephrol. 2007;20(Suppl. 12): S33–S38.
   PubMed Web of Science ®Google Scholar
• Durand PY. Iron therapy: Is it different with peritoneal dialysis compared to hemodialysis? Nephrol Ther. 2006;2(Suppl. 5): S341–S346.
   Google Scholar
• U.S. Renal Data System (USRDS). 2006 annual data report: Atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA; 2006.
   Google Scholar
• Ahsan N. Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: A prospective, cross-over trial. Adv Perit Dial. 2000;16:80–84.
   Google Scholar
• Macdougall IC. How to optimise anaemia therapy in peritoneal dialysis patients. Contrib Nephrol. 2006;150:202–213.
   PubMedGoogle Scholar
• Kapoian T, O'Mara NB, Singh AK, Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372–379.
   PubMedGoogle Scholar
• St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994–2002). Am J Kidney Dis. 2005;46(4):650–660.
   PubMed Web of Science ®Google Scholar
• Allen JR, Troidle LK, Juergensen PH, Kliger AS, Finkelstein FO. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran. Perit Dial Int. 2000;20(6):674–678.
   Google Scholar
• Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433–439.
   Google Scholar
• Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int. 1996;16(6):646–648.
   Google Scholar
• Pecoits-Filho RF, Twardowski ZJ, Kim YL, Khanna R, Morre H, Nolph KD. The absence of toxicity in intraperitoneal iron dextran administration: A functional and histological analysis. Perit Dial Int. 1998;18(1):64–70.
   Google Scholar
• Reddy DK, Moore HL, Lee JH, Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int. 2001;59(2):764–773.
   Google Scholar
• Mars RL, Moles K, Pope K, Hargrove P. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial. 1999; 15:60–64.
   Google Scholar
• Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int. 2001;21(3):290–295.
   Google Scholar
• Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl. 1999; 69:S71–S78.
   Google Scholar
• Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int. 2008;28(2):149–154.
   Google Scholar
• Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: A randomized, controlled trial. Clin J Am Soc Nephrol. 2006; 1(3):475–482.
   Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378–382.
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care. 2009;35(Suppl. 2):8–13.
   Google Scholar
• Sav T, Tokgoz B, Sipahioglu MH, Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29(4):423–426.
   PubMed Web of Science ®Google Scholar
• Sinha S, Chiu DY, Peebles G, Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. J Ren Care. 2009;35(2):67–73.
   Google Scholar
• Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008; 73(5):528–530.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med. 20075;357(1):93–94.
   Google Scholar